The Effects of Bariatric Surgery on Type 2 Diabetes in Asian Populations: a Meta-analysis of Randomized Controlled Trials

  • 74 Accesses



To evaluate the effects of bariatric surgery on patients with type 2 diabetes through comparing Asian and non-Asian populations according to follow-up time.


In this meta-analysis of randomized controlled trials (RCTs), we searched PubMed databases for relevant articles. A meta-analysis was undertaken of 37 eligible RCTs.


Diabetes remission rates among Asian populations were similar to those of non-Asian populations at 1 year (95% confidence interval (CI) 0.519 [0.417, 0.619] vs 0.571 [0.316, 0.794], respectively) but were found to be higher in Asian populations at 2 years compared to non-Asian populations (95% CI 0.672 [0.469, 0.826] vs 0.563 [0.220, 0.855], respectively). Asian populations showed greater reductions in HbA1c (− 3.512 [− 2.726, − 4.299], − 3.001 [− 1.433, − 4.569], and − 3.345 [− 2.267, − 4.423]) than non-Asian populations (− 2.129 [− 1.821, − 2.438], − 2.301 [− 1.881, − 2.722], and − 2.107 [− 1.941, − 2.273]) at 1, 2, and 5 years, respectively. Asian populations also showed greater reductions of fasting plasma glucose than non-Asian populations, and these effects were prominent at 3- and 5-year follow-up (Asian populations, − 83.297 [− 73.264, − 93.331]; non-Asian populations, − 54.288 [− 37.409, − 71.166] at 3 years; Asian populations, − 99.014 [− 82.239, − 115.788]; non-Asian populations, − 45.756 [− 21.892, − 69.621] at 5 years).


Bariatric surgery is more successful in diabetes remission and glucose outcome improvement in Asian populations with type 2 diabetes than in non-Asian populations, even over long-term follow-up periods. Bariatric surgery can be considered an effective treatment option and may present an appropriate opportunity to improve the prognosis for Asian patients with type 2 diabetes.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.

Fig. 1


  1. 1.

    Chatterjee S, Khunti K, Davies MJ, et al. Type 2 diabetes. Lancet. 2017;389:2239–51.

  2. 2.

    Feldman AL, Griffin SJ, Ahern AL, et al. Impact of weight maintenance and loss on diabetes risk and burden: a population-based study in 33,184 participants. BMC Public Health. 2017;17:170.

  3. 3.

    Won JC, Lee JH, Kim JH, et al. Diabetes Fact Sheet in Korea, 2016: an appraisal of current status. Diabetes Metab J. 2018;42:415–24.

  4. 4.

    Buchwald H, Buchwald JN. Metabolic (Bariatric and Nonbariatric) Surgery for Type 2 diabetes: a personal perspective review. Diabetes Care. 2019;42:331–40.

  5. 5.

    Schauer PR, Mingrone G, Ikramuddin S, et al. Clinical outcomes of metabolic surgery: efficacy of glycemic control, weight loss, and remission of diabetes. Diabetes Care. 2016;39:902–11.

  6. 6.

    Rubio-Almanza M, Hervás-Marín D, Cámara-Gómez R, et al. Does metabolic surgery lead to diabetes remission in patients with BMI < 30 kg/m2?: a meta-analysis. Obes Surg. 2019;29:1105–16.

  7. 7.

    Sheng B, Truong K, Spitler H, et al. The long-term effects of bariatric surgery on type 2 diabetes remission, microvascular and macrovascular complications, and mortality: a systematic review and meta-analysis. Obes Surg. 2017;27:2724–32.

  8. 8.

    Morton JM. Ethnic considerations for metabolic surgery. Diabetes Care. 2016;39:949–53.

  9. 9.

    Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci. 2013;1281:62–91.

  10. 10.

    Ji G, Li P, Li W, et al. The effect of bariatric surgery on Asian patients with type 2 diabetes mellitus and body mass index < 30 kg/m2: a systematic review and meta-analysis. Obes Surg. 2019

  11. 11.

    Yeo D, Yeo C, Low TY, et al. Outcomes after metabolic surgery in Asians-a meta-analysis. Obes Surg. 2019;29:114–26.

  12. 12.

    Foschi D, Sorrentino L, Tubazio I, et al. Ileal interposition coupled with duodenal diverted sleeve gastrectomy versus standard medical treatment in type 2 diabetes mellitus obese patients: long-term results of a case-control study. Surg Endosc. 2019;33:1553–63.

  13. 13.

    Simonson DC, Halperin F, Foster K, et al. Clinical and patient-centered outcomes in obese patients with type 2 diabetes 3 years after randomization to Roux-en-Y gastric bypass surgery versus intensive lifestyle management: the SLIMM-T2D study. Diabetes Care. 2018;41:670–9.

  14. 14.

    Crawford MR, Pham N, Khan L, et al. Increased bone turnover in type 2 diabetes patients randomized to bariatric surgery versus medical therapy at 5 years. Endocr Pract. 2018;24:256–64.

  15. 15.

    Murphy R, Clarke MG, Evennett NJ, et al. Laparoscopic sleeve gastrectomy versus banded Roux-en-Y gastric bypass for diabetes and obesity: a prospective randomised double-blind trial. Obes Surg. 2018;28:293–302.

  16. 16.

    Salminen P, Helmiö M, Ovaska J, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS randomized clinical trial. JAMA. 2018;319:241–54.

  17. 17.

    Casajoana A, Pujol J, Garcia A, et al. Predictive value of gut peptides in T2D remission: randomized controlled trial comparing metabolic gastric bypass, sleeve gastrectomy and greater curvature plication. Obes Surg. 2017;27:2235–45.

  18. 18.

    Gómez-Ambrosi J, Gallego-Escuredo JM, Catalán V, et al. FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss. Clin Nutr. 2017;36:861–8.

  19. 19.

    Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017;376:641–51.

  20. 20.

    Chong K, Ikramuddin S, Lee WJ, et al. National differences in remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery-subgroup analysis of 2-year results of the diabetes surgery study comparing Taiwanese with Americans with mild obesity (BMI 30–35 kg/m2). Obes Surg. 2017;27:1189–95.

  21. 21.

    Murphy R, Tsai P, Jüllig M, et al. Differential changes in gut microbiota after gastric bypass and sleeve gastrectomy bariatric surgery vary according to diabetes remission. Obes Surg. 2017;27:917–25.

  22. 22.

    Panosian J, Ding SA, Wewalka M, et al. Physical activity in obese type 2 diabetes after gastric bypass or medical management. Am J Med. 2017;130:83–92.

  23. 23.

    Ikramuddin S, Korner J, Lee WJ, et al. Durability of addition of Roux en-Y gastric bypass to lifestyle intervention and medical management in achieving primary treatment goals for uncontrolled type 2 diabetes in mild-to moderate obesity: a randomized control trial. Diabetes Care. 2016;39:1510–8.

  24. 24.

    Cummings DE, Arterburn DE, Westbrook EO, et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. Diabetologia. 2016;59:945–53.

  25. 25.

    Tang Q, Sun Z, Zhang N, et al. Cost-effectiveness of bariatric surgery for type 2 diabetes mellitus: a randomized controlled trial in China. Medicine. 2016;95:e3522.

  26. 26.

    Sachdev S, Wang Q, Billington C, et al. FGF 19 and bile acids increase following Roux-en-Y gastric bypass but not after medical management in patients with type 2 diabetes. Obes Surg. 2016;26:957–65.

  27. 27.

    Panunzi S, Carlsson L, De Gaetano A, et al. Determinants of diabetes remission and glycemic control after bariatric surgery. Diabetes Care. 2016;39:166–74.

  28. 28.

    Steven S, Hollingsworth KG, Small PK, et al. Weight loss decreases excess pancreatic triacylglycerol specifically in type 2 diabetes. Diabetes Care. 2016;39:158–65.

  29. 29.

    Martinussen C, Bojsen-Møller KN, Dirksen C, et al. Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass. Am J Physiol Endocrinol Metab. 2015;308:E535–44.

  30. 30.

    Courcoulas AP, Belle SH, Neiberg RH, et al. Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment: a randomized clinical trial. JAMA Surg. 2015;150:931–40.

  31. 31.

    Petry TZ, Fabbrini E, Otoch JP, et al. Effect of duodenal-jejunal bypass surgery on glycemic control in type 2 diabetes: a randomized controlled trial. Obesity. 2015;23:1973–9.

  32. 32.

    Nguyen KT, Billington CJ, Vella A, et al. Preserved insulin secretory capacity and weight loss are the predominant predictors of glycemic control in patients with type 2 diabetes randomized to Roux-en-Y gastric bypass. Diabetes. 2015;64:3104–10.

  33. 33.

    Yang J, Wang C, Cao G, et al. Long-term effects of laparoscopic sleeve gastrectomy versus roux-en-Y gastric bypass for the treatment of Chinese type 2 diabetes mellitus patients with body mass index 28-35 kg/m2. BMC Surg. 2015;15:88.

  34. 34.

    Ding SA, Simonson DC, Wewalka M, et al. Adjustable gastric band surgery or medical management in patients with type 2 diabetes: a randomized clinical trial. J Clin Endocrinol Metab. 2015;100:2546–56.

  35. 35.

    Ikramuddin S, Billington CJ, Lee WJ, et al. Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial. Lancet Diabetes Endocrinol. 2015;3:413–22.

  36. 36.

    Yi B, Jiang J, Zhu L, et al. Comparison of the effects of Roux-en-Y gastrojejunostomy and LRYGB with small stomach pouch on type 2 diabetes mellitus in patients with BMI<35kg/m(2). Surg Obes Relat Dis. 2015;11:1061–8.

  37. 37.

    Risstad H, Søvik TT, Engström M, et al. Five-year outcomes after laparoscopic gastric bypass and laparoscopic duodenal switch in patients with body mass index of 50 to 60. JAMA Surg. 2015;150:352–61.

  38. 38.

    Ren Y, Yang W, Yang J, et al. Effect of Roux-en-Y gastric bypass with different pouch size in Chinese T2DM patients with BMI 30–35 kg/m2. Obes Surg. 2015;25:457–63.

  39. 39.

    Lee WJ, Chong K, Lin YH, et al. Laparoscopic sleeve gastrectomy versus single anastomosis (Mini-) gastric bypass for the treatment of type 2 diabetes mellitus: 5-year results of a randomized trial and study of incretin effect. Obes Surg. 2014;24:1552–62.

  40. 40.

    Courcoulas AP, Goodpaster BH, Eagleton JK, et al. Surgical vs medical treatments for type 2 diabetes mellitus: a randomized clinical trial. JAMA Surg. 2014;149:707–15.

  41. 41.

    Khoo CM, Chen J, Pamuklar Z, et al. Effects of Roux-en-Y gastric bypass or diabetes support and education on insulin sensitivity and insulin secretion in morbidly obese patients with type 2 diabetes. Ann Surg. 2014;259:494–501.

  42. 42.

    Kashyap SR, Bhatt DL, Wolski K, et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes. Diabetes Care. 2013;36:2175–82.

  43. 43.

    Liang Z, Wu Q, Chen B, et al. Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trial. Diabetes Res Clin Pract. 2013;101:50–6.

  44. 44.

    Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia. JAMA. 2013;309:2240–9.

  45. 45.

    Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567–76.

  46. 46.

    Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577–85.

  47. 47.

    Lee WJ, Chen CY, Chong K, et al. Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. Surg Obes Relat Dis. 2011;7:683–90.

  48. 48.

    Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316–23.

  49. 49.

    Koliaki C, Liatis S, le Roux CW, et al. The role of bariatric surgery to treat diabetes: current challenges and perspectives. BMC Endocr Disord. 2017;17:50.

  50. 50.

    Cummings DE, Rubino F. Metabolic surgery for the treatment of type 2 diabetes in obese individuals. Diabetologia. 2018;61:257–64.

  51. 51.

    Pareek M, Schauer PR, Kaplan LM, et al. Metabolic surgery: weight loss, diabetes, and beyond. J Am Coll Cardiol. 2018;71:670–87.

  52. 52.

    Mulla CM, Middelbeek RJW, Patti ME, et al. Mechanisms of weight loss and improved metabolism following bariatric surgery. Ann N Y Acad Sci. 2018;1411:53–64.

  53. 53.

    Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39:861–77.

  54. 54.

    Admiraal WM, Celik F, Gerdes VE, et al. Ethnic differences in weight loss and diabetes remission after bariatric surgery: a meta-analysis. Diabetes Care. 2012;35:1951–8.

  55. 55.

    le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg. 2007;246:780–5.

  56. 56.

    Dar MS, Chapman 3rd WH, Pender JR, et al. GLP-1 response to a mixed meal: what happens 10 years after Roux-en-Y gastric bypass (RYGB)? Obes Surg. 2012;22:1077–83.

  57. 57.

    Zhang F, Tang X, Cao H. Impaired secretion of total glucagon-like peptide-1 in people with impaired fasting glucose combined impaired glucose tolerance. Int J Med Sci. 2012;9:574–81.

  58. 58.

    Yabe D, Kuroe A, Lee S, et al. Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: comparison of type 2 diabetes patients and healthy controls. J Diabetes Investig. 2010;1:56–9.

  59. 59.

    Wang W, Nevárez L, Filippova E, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: a 52-week open-label, randomized phase III trial. Diabetes Obes Metab. 2019;21:234–43.

  60. 60.

    Kim YG, Hahn S, Oh TJ, et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56:696–708.

  61. 61.

    Kim YG, Hahn S, Oh TJ, et al. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:900–9.

Download references

Author information

Correspondence to Sang Yong Kim.

Ethics declarations

Ethical Approval and Consent

For this type of study, formal consent is not required. Informed consent does not apply.

Conflict of Interest

The authors declare that that have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kim, J.H., Pyo, J., Cho, W.J. et al. The Effects of Bariatric Surgery on Type 2 Diabetes in Asian Populations: a Meta-analysis of Randomized Controlled Trials. OBES SURG (2019) doi:10.1007/s11695-019-04257-w

Download citation


  • Bariatric surgery
  • Type 2 diabetes
  • Asian
  • Meta-analysis